4.16
0.14 (3.48%)
| Previous Close | 4.02 |
| Open | 4.02 |
| Volume | 2,649,734 |
| Avg. Volume (3M) | 3,716,911 |
| Market Cap | 482,439,904 |
| Price / Earnings (Forward) | 15.36 |
| Price / Sales | 0.230 |
| Price / Book | 0.550 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -4.54% |
| Operating Margin (TTM) | 0.35% |
| Diluted EPS (TTM) | -1.23 |
| Quarterly Revenue Growth (YOY) | -24.40% |
| Total Debt/Equity (MRQ) | 77.09% |
| Current Ratio (MRQ) | 0.990 |
| Operating Cash Flow (TTM) | 18.42 M |
| Levered Free Cash Flow (TTM) | 2.23 M |
| Return on Assets (TTM) | -0.04% |
| Return on Equity (TTM) | -9.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Bearish |
| Health Information Services (Global) | Bearish | Bearish | |
| Stock | Evolent Health, Inc | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 1.50 |
|
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Value |
| % Held by Insiders | 1.55% |
| % Held by Institutions | 108.63% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cadian Capital Management, Lp | 30 Sep 2025 | 11,728,924 |
| Eventide Asset Management, Llc | 30 Sep 2025 | 6,292,511 |
| Rubicon Founders Llc | 30 Sep 2025 | 5,816,123 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 16.00 (BTIG, 284.62%) | Buy |
| Median | 9.50 (128.37%) | |
| Low | 6.00 (Citigroup, 44.23%) | Buy |
| Average | 9.63 (131.49%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 4.35 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 09 Jan 2026 | 6.00 (44.23%) | Buy | 4.17 |
| 21 Nov 2025 | 9.50 (128.37%) | Buy | 4.14 | |
| Citizens | 06 Jan 2026 | 10.00 (140.38%) | Buy | 4.02 |
| 10 Nov 2025 | 11.00 (164.42%) | Buy | 4.95 | |
| JP Morgan | 17 Nov 2025 | 7.00 (68.27%) | Buy | 3.87 |
| Canaccord Genuity | 14 Nov 2025 | 9.00 (116.35%) | Buy | 4.18 |
| BMO Capital | 13 Nov 2025 | 7.00 (68.27%) | Buy | 4.16 |
| Oppenheimer | 12 Nov 2025 | 12.00 (188.46%) | Buy | 4.45 |
| Truist Securities | 10 Nov 2025 | 10.00 (140.38%) | Buy | 4.95 |
| BTIG | 07 Nov 2025 | 16.00 (284.62%) | Buy | 4.96 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Jan 2026 | Announcement | Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08 |
| 06 Nov 2025 | Announcement | Evolent and American Oncology Network unveil innovative model seeking to improve cancer care while eliminating prior authorization burden |
| 06 Nov 2025 | Announcement | Evolent Announces Third Quarter 2025 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |